Evaluation of the impacts of antibiotic drugs on PON 1; a major bioscavenger against cardiovascular diseases

被引:49
作者
Ekinci, Deniz [1 ]
Beydemir, Suekrue [1 ,2 ]
机构
[1] Ataturk Univ, Fac Sci, Dept Chem, Div Biochem, TR-25240 Erzurum, Turkey
[2] Ataturk Univ, Biotechnol Applicat & Res Ctr, TR-25240 Erzurum, Turkey
关键词
Paraoxonase; Inhibition; Antibiotic; Atherosclerosis; Organophosphate; LOW-DENSITY-LIPOPROTEIN; SERUM PARAOXONASE; IN-VITRO; BIOLOGICAL-ACTIVITY; OXIDATIVE STRESS; HDL; ATHEROSCLEROSIS; PROTEIN; PLASMA; ENZYME;
D O I
10.1016/j.ejphar.2009.06.048
中图分类号
R9 [药学];
学科分类号
100702 [药剂学];
摘要
Paroxonase 1(PON1) is an antiatherogenic enzyme which is also an organophosphate hydrolyzer. It has crucial roles in detoxification of highly toxic substances and protecting LDL against oxidation. Decrease in the levels of this enzyme is a great risk for the patients with cardiovascular diseases, diabetes mellitus, chronic renal failure, rheumatoid arthritis, hyperthyroidism, and age-related macular degeneration. Therefore, inhibitors and activators of PON1 must be well-characterized, and drug studies would be a good starting point in this regard. Moreover, purification of PON1 has been a challenge for scientists due to its tight association with HDL. Here we report the purification of human serum PON1 using very simple methods and investigation of the interactions between the enzyme and some commonly used antibiotics. We purified PON1 from human serum with a high specific activity and used the pure enzyme for inhibition studies. We observed that some antibiotics inhibit the enzyme at very low doses while some are efficient at higher doses. The antibiotics exhibited different inhibition mechanisms. We concluded that usage of these antibiotics would be very dangerous in some cases. (C) 2009 Elsevier B.V. All rights reserved.
引用
收藏
页码:84 / 89
页数:6
相关论文
共 41 条
[1]
SERUM PARAOXONASE ACTIVITY, CONCENTRATION, AND PHENOTYPE DISTRIBUTION IN DIABETES-MELLITUS AND ITS RELATIONSHIP TO SERUM-LIPIDS AND LIPOPROTEINS [J].
ABBOTT, CA ;
MACKNESS, MI ;
KUMAR, S ;
BOULTON, AJ ;
DURRINGTON, PN .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1995, 15 (11) :1812-1818
[2]
Intravenous anesthetics inhibit human paraoxonase-1 (PON1) activity in vitro and in vivo [J].
Alici, Haci Ahmed ;
Ekinci, Deniz ;
Beydemir, Suekrue .
CLINICAL BIOCHEMISTRY, 2008, 41 (16-17) :1384-1390
[3]
Estimation of the upper limit of human butyrylcholinesterase dose required for protection against organophosphates toxicity: A mathematically based toxicokinetic model [J].
Ashani, Y ;
Pistinner, S .
TOXICOLOGICAL SCIENCES, 2004, 77 (02) :358-367
[4]
Paraoxonases 1, 2, and 3, oxidative stress, and macrophage foam cell formation during atherosclerosis development [J].
Aviram, M ;
Rosenblat, M .
FREE RADICAL BIOLOGY AND MEDICINE, 2004, 37 (09) :1304-1316
[5]
Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions - A possible peroxidative role for paraoxonase [J].
Aviram, M ;
Rosenblat, M ;
Bisgaier, CL ;
Newton, RS ;
Primo-Parmo, SL ;
La Du, BN .
JOURNAL OF CLINICAL INVESTIGATION, 1998, 101 (08) :1581-1590
[6]
Distribution spectrum of paraoxonase activity in HDL fractions [J].
Bergmeier, C ;
Siekmeier, R ;
Gross, W .
CLINICAL CHEMISTRY, 2004, 50 (12) :2309-2315
[7]
BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
[8]
Lipoprotein-associated inflammatory proteins: markers or mediators of cardiovascular disease? [J].
Chait, A ;
Han, CY ;
Oram, JF ;
Heinecke, JW .
JOURNAL OF LIPID RESEARCH, 2005, 46 (03) :389-403
[9]
Ciftci M, 2008, ASIAN J CHEM, V20, P2189
[10]
Morphine inhibits erythrocyte carbonic anhydrase in vitro and in vivo [J].
Coban, Taha Abdulkadir ;
Beydemir, Suekrue ;
Guelcin, Ilhami ;
Ekinci, Deniz .
BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2007, 30 (12) :2257-2261